A 1989 through 2009 hospital-based study in Ireland did not find overall survival differences between AYAs (n = 276) and older women when they adjusted for ER, PR, and HER2 status, although HER2 status was only 40% complete, and these three tumor markers were adjusted for separately in the analyses [17]. This evidence concerns the gene ESR1 and neoplasm.